Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Dapagliflozin on Cardiac Motion Metrics and Electrophysiological Function in Individuals with Type 2 Diabetes Mellitus and Coronary Artery Disease

  • By

  • Fang Liu

  • Rui Jin

  • June 4, 2026

Share

  • 1

    Dapagliflozin significantly improved cardiac function and myocardial performance in patients with T2DM and CHD compared to conventional treatment.

  • 2

    The dapagliflozin group showed greater enhancements in left ventricular ejection fraction and exercise tolerance after 4 weeks of treatment.

  • 3

    Dapagliflozin was associated with improved cardiac electrophysiological activity, including longer QT and Tp-Te intervals and reduced ST depression.

  • 4

    Adverse cardiovascular event rates were similar between the dapagliflozin and conventional treatment groups, indicating safety.

  • 5

    This study highlights the potential of dapagliflozin as an adjunctive therapy for improving cardiac outcomes in high-risk T2DM patients with CHD.

Original Source(s)

Related Content